Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 23, 2014Scientific ReportsOpen Access

Elevated circulating lipasin/betatrophin in human type 2 diabetes and obesity

View Full Paper
Ask AI
Bookmark
Share

Key result

Fasting serum lipasin levels were significantly increased by more than two-fold in patients with type 2 diabetes (5.56 ng/mL) compared to non-diabetic control subjects (2.19 ng/mL).

Why the study?

Are circulating levels of lipasin altered in human type 2 diabetes, obesity, and the postprandial state?

Population

94 human subjects in three cohorts: 1) 15 non-diabetic and 14 BMI- and age-matched type 2 diabetic subjects…

Design

Cross-sectional

Authors

ZFZhiyao FuFBFeven BerhaneAFAlemu Fite

Discussion

Loading...

Member takes

Overview

Elevated lipasin in type 2 diabetes should not change practice; hypothesis-generating for dyslipidemia links and requires prospective validation.

Study Design

Type

Cross-Sectional (n=94)

Multicenter

No

Structured PICO

Are circulating levels of lipasin altered in human type 2 diabetes, obesity, and the postprandial state?

P
Population
94 human subjects, including individuals with and without type 2 diabetes, lean and obese individuals, and healthy subjects evaluated before and after a defined meal, to assess circulating lipasin levels.
C
Comparator
Non-diabetic controls, lean controls, and fasting state
O
Outcome
Serum lipasin (betatrophin) levelssurrogate

Main Result

Absolute Event Rate: 5.56% vs 2.19%

p-value: p=<0.001

Lipasin (betatrophin) is a nutritionally-regulated hepatokine that is significantly elevated in human type 2 diabetes and obesity, potentially contributing to hypertriglyceridemia in these conditions.

Limitations

  • Only one time point was adopted in a limited number of subjects for examining postprandial lipasin levels.
  • Increased insulin levels in diabetic patients make it difficult to exclude the possibility that insulin, rather than glucose, was largely responsible for elevated lipasin.
  • Potential confounding factors of glucose and BMI limited the ability to examine the correlation between lipasin and lipid levels.
  • Only one time point was adopted in a limited number of subjects for postprandial lipasin levels

Cite This Study

Fu et al. (2014) conducted a cross-sectional in Type 2 diabetes and obesity (n=94). Type 2 diabetes vs. Non-diabetic controls was evaluated on Fasting serum lipasin levels (ng/mL) (p=<0.001). Fasting serum lipasin levels were significantly increased by more than two-fold in patients with type 2 diabetes (5.56 ng/mL) compared to non-diabetic control subjects (2.19 ng/mL).

synapsesocial.com/papers/6a98705ba184c7fb06ada29bhttps://doi.org/10.1038/srep05013
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Increased circulating levels of betatrophin in individuals with long-standing type 1 diabetes2013 · 133 citations
  2. 2Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism2012 · 301 citations
  3. 3Obesity and Diabetes in the Developing World — A Growing Challenge2007 · 2,222 citations
  4. 4Triglycerides and Cardiovascular Disease2011 · 1,892 citations
  5. 5Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis2013 · 327 citations